Non-[18F]FDG PET in clinical oncology

被引：92
作者：
Groves, Ashley M. [1 ]
Win, Thida
Ben Haim, Simona
Ell, Peter J.
机构：
[1] UCL, Inst Nucl Med, London NW1 2BU, England
[2] Lister Hosp, Stevenage, Herts, England
来源：
LANCET ONCOLOGY | 2007年 / 8卷 / 09期
关键词：
D O I：
10.1016/S1470-2045(07)70274-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PET is an exquisitely sensitive molecular imaging technique using positron-emitting radioisotopes coupled to specific ligands. Many biological targets of great interest can be imaged with these radiolabelled ligands. This review describes the current status of non-18-fluorodeoxyglucose PET tracers that have a potential clinical effect in oncology. With the help of these tracers, knowledge is being acquired on the molecular characterisation of specific tumours, their biological signature, and postinterventional response. The potential role of these imaging probes for tumour detection and monitoring is progressively being recognised by clinical oncologists, biologists, and pharmacologists.
引用
收藏
页码：822 / 830
页数：9
相关论文
共 76 条
  • [21] [18F]FLT PET for diagnosis and staging of thoracic tumours
    Dittmann, H
    Dohmen, BM
    Paulsen, F
    Eichhorn, K
    Eschmann, SM
    Horger, M
    Wehrmann, M
    Machulla, HJ
    Bares, R
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (10) : 1407 - 1412
  • [22] Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses:: a phase I trial
    Divgi, Chaitanya R.
    Pandit-Taskar, Neeta
    Jungbluth, Achim A.
    Reuter, Victor E.
    Gonen, Mithat
    Ruan, Shutian
    Pierre, Christine
    Nagel, Andrew
    Pryma, Daniel A.
    Humm, John
    Larson, Steven M.
    Old, Lloyd J.
    Russo, Paul
    [J]. LANCET ONCOLOGY, 2007, 8 (04) : 304 - 310
  • [23] Evaluation of primary pulmonary carcinoid tumors using FDG PET
    Erasmus, JJ
    McAdams, HP
    Patz, EF
    Coleman, RE
    Ahuja, V
    Goodman, PC
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1998, 170 (05) : 1369 - 1373
  • [24] Eschmann SM, 2005, J NUCL MED, V46, P253
  • [25] Even-Sapir E, 2006, J NUCL MED, V47, P287
  • [26] Is 11C-choline the most appropriate tracer for prostate cancer?
    Fazio, F
    Picchio, M
    Messa, C
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (05) : 753 - 756
  • [27] Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma
    Floeth, Frank W.
    Pauleit, Dirk
    Sabel, Michael
    Stoffels, Gabriele
    Reifenberger, Guido
    Riemenschneider, Markus J.
    Jansen, Paul
    Coenen, Heinz H.
    Steiger, Hans-Jakob
    Langen, Karl-Josef
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (04) : 519 - 527
  • [28] Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy--glucose in positron emission tomography for colorectal cancer
    Francis, DL
    Visvikis, D
    Costa, DC
    Arulampalam, THA
    Townsend, C
    Luthra, SK
    Taylor, I
    Ell, PJ
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (07) : 988 - 994
  • [29] 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors:: Comparison with somatostatin receptor scintigraphy and CT
    Gabriel, Michael
    Decristoforo, Clemens
    Kendler, Dorota
    Dobrozemsky, Georg
    Heute, Dirk
    Uprimny, Christian
    Kovacs, Peter
    Von Guggenberg, Elisabeth
    Bale, Reto
    Virgolini, Irene J.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (04) : 508 - 518
  • [30] Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
    Ginj, Mihaela
    Zhang, Hanwen
    Waser, Beatrice
    Cescato, Renzo
    Wild, Damian
    Wang, Xuejuan
    Erchegyi, Judit
    Rivier, Jean
    Maecke, Helmut R.
    Reubi, Jean Claude
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (44) : 16436 - 16441
12345678